Placebo News and Research

RSS

Possible overlap exists between inflammatory bowel disease and IBS

Research unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas suggests a possible overlap of symptoms of two prevalent GI disorders: irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) and further suggests a possible link between subtle GI tract inflammation and IBS symptoms-a link that is also the focus of the first systemic review of the literature on this topic and an editorial both published in this month's American Journal of Gastroenterology.

23 Oct 2012

Eisai receives FDA approval for Fycompa to treat partial onset seizures

The U.S. Food and Drug Administration today approved Fycompa (perampanel) tablets to treat partial onset seizures in patients with epilepsy ages 12 years and older.

23 Oct 2012

Multivitamin use may protect men from cancer

Men who take a daily multivitamin supplement have a modest reduction in their risk for developing cancer, suggest results from the Physicians’ Health Study II.

22 Oct 2012

$Ustekinumab success in refractory Crohn’s disease$

Ustekinumab success in refractory Crohn’s disease

Patients with Crohn’s disease who have failed to respond adequately to anti–tumor necrosis factor treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind, placebo-controlled trial suggest.

22 Oct 2012

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.

22 Oct 2012

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Chinese herbs, including JHQG, BFXL, and BFHX, may show significant benefits for patients with non-small cell lung cancer (NSCLC), idiopathic pulmonary fibrosis (IPF), and influenza.

22 Oct 2012

Bayer announces data from riociguat Phase III pulmonary arterial hypertension trial

Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.

22 Oct 2012

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Neuralstem, Inc. announced that it has begun dosing the second cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

19 Oct 2012

Researchers identify brain mechanisms that regulate cocaine-seeking behavior

Researchers from the University of Wisconsin-Milwaukee (UWM) have identified mechanisms in the brain responsible for regulating cocaine-seeking behavior, providing an avenue for drug development that could greatly reduce the high relapse rate in cocaine addiction.

19 Oct 2012

Long-term multivitamin use associated with prevention of cancer in middle-aged and older men

In a randomized trial that included nearly 15,000 male physicians, long-term daily multivitamin use resulted in a modest but statistically significant reduction in cancer after more than a decade of treatment and follow-up, according to a study appearing in JAMA.

19 Oct 2012

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine.

18 Oct 2012

Personalized medicine research strikes early for heart genes

A landmark paper identifying genetic signatures that predict which patients will respond to a life-saving drug for treating congestive heart failure has been published by a research team co-led by Stephen B. Liggett, MD, of the University of South Florida.

18 Oct 2012

Health benefits of fibrate add-on detected postprandially

Adding fenofibrate to statin treatment significantly improves postprandial triglyceride response over statin treatment alone in individuals with diabetes, show findings from a US study.

18 Oct 2012

Health benefits of fibrate add-on detected postprandially

Adding fenofibrate to statin treatment significantly improves postprandial triglyceride response over statin treatment alone in individuals with diabetes, show findings from a US study.

18 Oct 2012

Study examines long-term affect of multivitamins on major chronic diseases

A daily multivitamin can help a man reduce his risk of cancer, according to new research from Brigham and Women's Hospital.

18 Oct 2012

Value of cranberries for UTI prevention called into question

Results from an updated systematic review suggest that the value of cranberry juice or capsule consumption for prevention of urinary tract infections is likely to be limited.

17 Oct 2012

Quinic acid derivative shows promise for treating radiation exposure

A quinic acid derivative, known as KZ-41, increases 30-day survival threefold compared with placebo when given to rats 24 hours after exposure to high levels of radiation.

17 Oct 2012

Botulinum treatment benefits in BPH maybe down to placebo effect

Treatment with botulinum toxin has proved no more effective than placebo at reducing symptoms in men with lower urinary tract symptoms due to benign prostate hyperplasia, show study findings.

17 Oct 2012

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.

17 Oct 2012

Novel drug increases survival in animal models exposed to high-dose radiation

A novel drug that mimics a naturally occurring molecule found in coffee and blueberries has been developed to treat radiation exposure. Charles R. Yates, Pharm.D., Ph.D., and colleagues Duane Miller, Ph.D., and Waleed Gaber, Ph.D., from the University of Tennessee Health Science Center and Baylor College of Medicine, show that application of this drug, starting 24 hours after radiation exposure, increases survival in animal models by three-fold compared to placebo.

17 Oct 2012

Placebo News and Research

Possible overlap exists between inflammatory bowel disease and IBS

Eisai receives FDA approval for Fycompa to treat partial onset seizures

Multivitamin use may protect men from cancer

Ustekinumab success in refractory Crohn’s disease

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Bayer announces data from riociguat Phase III pulmonary arterial hypertension trial

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Researchers identify brain mechanisms that regulate cocaine-seeking behavior

Long-term multivitamin use associated with prevention of cancer in middle-aged and older men

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Personalized medicine research strikes early for heart genes

Health benefits of fibrate add-on detected postprandially

Health benefits of fibrate add-on detected postprandially

Study examines long-term affect of multivitamins on major chronic diseases

Value of cranberries for UTI prevention called into question

Quinic acid derivative shows promise for treating radiation exposure

Botulinum treatment benefits in BPH maybe down to placebo effect

Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Novel drug increases survival in animal models exposed to high-dose radiation

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News